Each month, we scan the regulatory landscape to bring you the latest developments shaping pharmaceutical and biotechnology innovation. In this roundup, you’ll find key publications that caught our attention, plus a curated summary of the most important regulatory news. Our goal is to highlight what matters, cut through the noise, and keep you up to date on changes that could impact drug development and market access in the UK, Europe and the US.
Regulatory Affairs News
The EMA welcomed political agreement on the new European Union (EU) pharmaceutical legislation
The EMA has welcomed a landmark political agreement, reached by the European Commission, the European Parliament and the Council of the European Union, on comprehensive reform of EU pharmaceutical legislation, marking the most significant regulatory overhaul in over 20 years. The reform modernises how medicines are developed, authorised and made available, simplifying and consolidating existing legislation, including rules for paediatric, rare disease and advanced therapy medicines.
Key changes include a simpler regulatory environment with a streamlined committee structure, faster assessment timelines and mandatory digital submissions and electronic product information. The legislation strengthens support for innovation through enhanced scientific advice, PRIME support, regulatory sandboxes, adapted frameworks for non-standard medicines, and improved paediatric development processes.
It also introduces stronger safeguards against medicine shortages, enhanced environmental risk assessments, and reinforced measures on antimicrobial resistance. Following formal approval, the EMA will develop guidance and engage stakeholders to support smooth implementation.
The FDA announced the second batch of national priority vouchers
The FDA announced six additional awardees under the Commissioner’s National Priority Voucher pilot programme, bringing the total recipients to 15. The programme aims to accelerate the review of products that address key national health priorities. Voucher holders may receive a regulatory decision within months of submitting a complete application, significantly shorter than standard timelines, subject to additional company requirements and FDA discretion to extend reviews if needed.
A central feature of the programme is a 1-day, multidisciplinary “tumour board–style” meeting that enables team-based scientific and clinical review. The initiative is enabled by existing U.S. legislation that allows the FDA to pilot innovative regulatory approaches to improve public health preparedness and access to safe, effective therapies.
The newly selected products target areas including cancer, tuberculosis, sickle cell disease, and obesity.
The FDA announced it is expanding its artificial intelligence (AI) capabilities: deploying agentic AI
The FDA announced the deployment of agentic AI capabilities for all agency employees, enabling more complex, multi-step AI workflows that support planning, reasoning and execution with built-in human oversight. Use of the tools is voluntary. The rollout builds on the earlier deployment of Elsa, a Large Language Model-based tool adopted by over 70% of staff and refined through ongoing feedback.
Developed within a secure GovCloud environment, the AI models do not train on FDA or industry-submitted data, protecting sensitive information. The new capabilities will support a wide range of activities, including pre- and post-market reviews, inspections, compliance, meeting management and administrative functions, helping drive operational efficiency.
To encourage innovation, the FDA is launching a 2-month Agentic AI Challenge, with staff showcasing solutions at FDA Scientific Computing Day in January 2026.
Publications that caught our eye
- From the ESMO Congress 2025. Nature Reviews Clinical Oncology.
- The EMA as a potential driver of competitiveness of orphan medicines in Europe: a focus on regulatory incentives and funding opportunities. Orphan Journal of Rare Diseases.
- FDA approves 100th small-molecule kinase inhibitor. Nature Reviews Drug Discovery.
- Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot. Nature Reviews Drug Discovery.
- Cancer cell therapies: global clinical trial trends and emerging directions. Nature Reviews Drug Discovery.
- The evolution of the obesity drug market. Nature Reviews Drug Discovery.
